398-90-3

Basic information

• Product Name: 2',5'-DIFLUOROACETANILIDE
• Synonyms: 2',5'-DIFLUOROACETANILIDE;2,5-DIFLUOROACETANILIDE;N-(2,5-difluorophenyl)acetamide;N-(2,5-difluorophenyl)ethanamide
• CAS NO: 398-90-3
• Molecular Formula: C₈H₇F₂NO
• Molecular Weight: 171.14
• Mol File: 398-90-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 277℃
• Flash Point: 121℃
• Appearance: /
• Density: 1.307
• Vapor Pressure: 0.00468mmHg at 25°C
• Refractive Index: 1.531
• PKA: 13.25±0.70(Predicted)
• CAS DataBase Reference: 2',5'-DIFLUOROACETANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2',5'-DIFLUOROACETANILIDE(398-90-3)
• EPA Substance Registry System: 2',5'-DIFLUOROACETANILIDE(398-90-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 398-90-3(Hazardous Substances Data)

Usage

General Description

2',5'-Difluoroacetanilide is a chemical compound characterized by the presence of a carbonyl group linked to a secondary amine. Its molecular formula is C8H8F2NO and it has a molar mass of 185.152 g/mol. It includes elements such as carbon, hydrogen, fluorine, and nitrogen. 2',5'-Difluoroacetanilide is widely used as an intermediate in the organic synthesis of other chemical substances. It falls under the category of anilide and displays typical anilide properties. Its physical and chemical properties may vary depending on the alterations and reactions the compound might undergo.

InChI:InChI=1/C8H7F2NO/c1-5(12)11-8-4-6(9)2-3-7(8)10/h2-4H,1H3,(H,11,12)

Upstream product

• 367-30-6 2,5-difluoroaniline 
• 75-36-5 acetyl chloride 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 108-24-7 acetic anhydride 

Downstream Products

• 1542-36-5 2,5-difluoro-4-nitroaniline 
• 399-75-7 5-fluoro-2-methyl-1,3-benzothiazole 
• 131105-89-0 2-amino-4-fluorobenzene-1-thiol 
• 1019585-90-0 2,5-difluorophenylethylamine 
• 1454650-58-8 N-5-dipropyl-4-fluoro-2-nitrobenzenediamine 
• 1454650-56-6 1,4-diamino-2-butylamino-5-propylamino benzene 
• 1454650-61-3 2-butylamino-5-propylamino-1,4-dinitrobenzene 
• 1454650-60-2 N-2,5-dinitro-4-butylaminophenyl-N-propyl-2,2,2-trifluoroacetamide 
• 1454650-59-9 4-fluoro-2,5-dinitro-N-propyl-N-trifluoroacetylbenzeneamine 
• 1454650-57-7 4-fluoro-2,5-dinitro-N-propylbenzeneamine 
• 366-53-0 N-(2,5-difluoro-4-nitrophenyl)-acetamide 
• 1374780-46-7 N,N'-[2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)-1,4-phenylene]diacetamide 
• 1374780-44-5 N,N'-[2,5-di(morpholin-4-yl)-1,4-phenylene]diacetamide 
• 1374780-43-4 1-[2,5-dinitro-4-(pyrrolidin-1-yl)phenyl]piperidine 

Relevant articles and documents

COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF

The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.

Synthesis and toxicity of new ring-fused imidazo[5,4-f] benzimidazolequinones and mechanism using amine N-oxide cyclizations

A new synthetic route to ring-fused imidazo[5,4-f]benzimidazoles is reported that can be used to access symmetrical and unsymmetrical quinone anticancer agents. Oxone in formic acid allows cyclisation of o-tert-aminoacetanilides to give ring-fused benzimi

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC50 of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED50's of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t1/2, 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (Cmax in sciatic nerve and eye are 2.36 and 1.45 μg equiv/g, respectively, when dosed with [14C] lidorestat at 10 mg/kg po).